Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies

NCT06458712 is registered in ClinicalTrials.gov with Duke Street Bio Ltd as lead sponsor.

NCT NCT06458712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06458712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies
Lead sponsor
Duke Street Bio Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
November 21, 2024
Completion date
December 31, 2028
Enrollment
180 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancers (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain mets) with specific mutations (homologous recombination deficiency)